Floatz logo

Olaparib

BRCA2-Related Cancer Predisposition

GBG Forschungs GmbHSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the BRCA2-Related Cancer Predisposition cohort.

Asset / SponsorPhaseRating
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
Talazoparib
Brown University
Phase 3BB
Ovitrelle
University Hospital, Ghent
Phase 4BB
Letrozole
UNICANCER
Phase 3BB
Niraparib
Qian Qin
Phase 3BB

View all 44 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
fallopian tube serous adenocarcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →